RxDoctor Payments Data

Rubin Thomas, MD

Internal Medicine · Rowlett, TXNPI 1750724001

Payments from drug & device makers

$1,642in general payments, 2019–2025

Across 86 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$528
  • Exact Sciences$316
  • Pfizer$147
  • GSK$110
  • Lilly USA, LLC$85
  • Bayer$72
  • plus $384 from 14 others

What the payments were for

  • Food & beverage$1,642100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,642 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$145,862
Medicare patients
291
Services billed
2,147

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin67$63,071
FarxigaDapagliflozin Propanediol67$60,883
OzempicSemaglutide35$57,755
TrulicityDulaglutide24$37,636
RybelsusSemaglutide20$33,821
JanuviaSitagliptin Phosphate26$32,878
EliquisApixaban31$29,850
XareltoRivaroxaban16$22,427
MounjaroTirzepatide17$19,302
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$15,060
LivaloPitavastatin Calcium16$8,371
MyrbetriqMirabegron13$8,107
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$5,711
Breo ElliptaFluticasone/Vilanterol13$5,374
Rosuvastatin Calcium323$3,867

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$528$91,57655 claims
Boehringer IngelheimJardiance$19$63,07167 claims
AstraZenecaFarxiga$63$60,88367 claims
Lilly USA, LLCTrulicity, Mounjaro$85$56,93841 claims
MerckJanuvia$12$32,87826 claims
PfizerEliquis$147$29,85031 claims
Johnson & JohnsonXarelto$22$22,42716 claims
GSKTrelegy Ellipta, Breo Ellipta$110$20,43525 claims
AbbVieSynthroid$15$2,98329 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Rowlett

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →